(Q39353092)

English

Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement

scientific article published on May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

William E Whitehead

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Olafur S Palsson

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Rona L Levy

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Andrew D Feld

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Michael VonKorff

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Marsha Turner

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

1 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

101

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1057-1065

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

The usual medical care for irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Sexual and physical abuse and gastrointestinal illness. Review and recommendations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Comparison of treatment outcome measures for irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00535.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2006.00535.X

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39353092&oldid=1822781384"